ImmuCell Stock

ImmuCell EBIT Margin

The EBIT Margin (Operating Margin) of ImmuCell (ICCC) as of Jul 27, 2026 is 5.97 %. In the previous year, EBIT Margin (Operating Margin) was -6.25 % — a change of -195.47% (higher).

EBIT Margin

5.97 %

YoY

-195.47%

Last updated:

EBIT Margin (Operating Margin) of ImmuCell is 2026 5.97 % . EBIT Margin (Operating Margin) of ImmuCell was 2025 -6.25 % . It decreases by -195.47% higher compared to the previous year.

ImmuCell's operating (EBIT) margin stands at 6.0%, up from 1.3% several years earlier.

Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

EBIT Margin (Operating Margin) of ImmuCell is 5.97 % in 2026.

Access this data via the Eulerpool API

Margins — ImmuCell

All Key Metrics — ImmuCell